T. Rowe Price Associates
ORTX

T. Rowe Price Associates’s Orchard Therapeutics plc American Depositary Shares ORTX Stock Holding History

T. Rowe Price Associates’s Portfolio ORTX Stock Details ORTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-133,037
Closed -$3.06M – 3056
2021
Q3 		$3.06M Sell
133,037
-1,249
-0.9% -$37.2K ﹤0.01% 1602
2021
Q2 		$5.89M Sell
134,286
-667
-0.5% -$37.2K ﹤0.01% 1484
2021
Q1 		$9.8M Sell
134,953
-131
-0.1% -$9.3K ﹤0.01% 1398
2020
Q4 		$5.84M Sell
135,084
-174,233
-56% -$7.8M ﹤0.01% 1423
2020
Q3 		$12.7M Sell
309,317
-181,995
-37% -$9.41M ﹤0.01% 1246
2020
Q2 		$29.5M Buy
491,312
+55,642
+13% +$5.1M ﹤0.01% 1020
2020
Q1 		$32.8M Sell
435,670
-111,276
-20% -$12.8M 0.01% 917
2019
Q4 		$75.2M Buy
546,946
+51,478
+10% +$6.26M 0.01% 763
2019
Q3 		$58.9M Buy
495,468
+90,812
+22% +$12.7M 0.01% 806
2019
Q2 		$56.6M Buy
404,656
+201,587
+99% +$35.4M 0.01% 839
2019
Q1 		$36.3M Buy
203,069
+11,916
+6% +$1.79M 0.01% 988
2018
Q4 		$30.1M Buy
+191,153
New +$28.5M 0.01% 1000

Other funds holding ORTX

Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

T. Rowe Price Associates's ORTX Position: Q4 2021 in Review

T. Rowe Price Associates sold out of Orchard Therapeutics plc American Depositary Shares (ORTX) in Q4 2021, closing a stake of 133,037 shares — an estimated $3.06M sold.

T. Rowe Price Associates first reported a position in ORTX in Q4 2018 and held it in 12 quarters. The position peaked at $75.2M in Q4 2019. 72 funds tracked by Wall St. Rank hold ORTX as of Q4 2021.

  • T. Rowe Price Associates reported no remaining Orchard Therapeutics plc American Depositary Shares position as of Q4 2021 after selling out during the quarter.
  • T. Rowe Price Associates sold 133,037 Orchard Therapeutics plc American Depositary Shares shares in Q4 2021, an estimated $3.06M.
  • T. Rowe Price Associates first reported a position in Orchard Therapeutics plc American Depositary Shares in Q4 2018 and held it in 12 quarters.
  • T. Rowe Price Associates's Orchard Therapeutics plc American Depositary Shares position peaked at $75.2M in Q4 2019.
  • 72 funds tracked by Wall St. Rank held Orchard Therapeutics plc American Depositary Shares as of Q4 2021.

Based on T. Rowe Price Associates's 13F filing for Q4 2021, filed 14 Feb 2022.